Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 8Lymphoma, Large-Cell, Anaplastic 6Lymphoma 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Non-Hodgkin 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Lymphoma, B-Cell 2Lymphatic Diseases 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasms by Histologic Type 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 4Rituximab 3cobomarsen 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2thymoglobulin 1ponatinib 1ibritumomab tiuxetan 1fludarabine phosphate 1fludarabine 1Vorinostat 1Tacrolimus 1Mycophenolic Acid 1Melphalan 1Imatinib Mesylate 1Ifosfamide 1Cytarabine 1Carmustine 1Carboplatin 1Busulfan 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immune System Diseases × Brentuximab Vedotin × Clear all
NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡